Cardiac involvement in African and American trypanosomiasis

The Lancet Infectious Diseases

Volumn 8, Issue 10, 2008, Pages 631-641

  Blum, Johannes A ^a   Zellweger, Michael J ^b   Burri, Christian ^a   Hatz, Christoph ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BENZNIDAZOLE; EFLORNITHINE; MELARSOPROL; PENTAMIDINE; PLACEBO; SOTALOL;

AFRICAN TRYPANOSOMIASIS; BRAIN DISEASE; CARDIOLOGY; CHAGAS DISEASE; DEFIBRILLATOR; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEVER; GASTROINTESTINAL SYMPTOM; HEART; HEART DISEASE; HEART TRANSPLANTATION; HUMAN; LABORATORY; LIFE CYCLE; NONHUMAN; PACEMAKER; PATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RADIOLOGY; REVIEW; SKIN ALLERGY; TRYPANOSOMA;

CHAGAS DISEASE; HEART DISEASES; HUMANS; TRYPANOSOMIASIS, AFRICAN;

EID: 52149092123     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70230-5     Document Type: Review

References (109)

1. Anez N., Carrasco H., Parada H., et al. Acute Chagas' disease in western Venezuela: a clinical, seroparasitologic, and epidemiologic study. Am J Trop Med Hyg 60 (1999) 215-222
2. Parada H., Carrasco H.A., Anez N., Fuenmayor C., and Inglessis I. Cardiac involvement is a constant finding in acute Chagas' disease: a clinical, parasitological and histopathological study. Int J Cardiol 60 (1997) 49-54
3. Pinto A.Y., Harada G.S., Valente V., et al. Cardiac attacks in patients with acute Chagas disease in a family micro-outbreak, in Abaetetuba, Brazilian Amazon. Rev Soc Bras Med Trop 34 (2001) 413-419 (in Portuguese).
4. Goldbaum M., Ajimura F.Y., Litvoc J., Carvalho S.A., and Eluf-Neto J. American trypanosomiasis and electrocardiographic alterations among industrial workers in Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo 46 (2004) 299-302
5. Barrett M.P., Burchmore R.J., Stich A., et al. The trypanosomiases. Lancet 362 (2003) 1469-1480
6. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1 (2001) 92-100
7. Salles G.F., Xavier S.S., Sousa A.S., Hasslocher-Moreno A., and Cardoso C.R. T-wave axis deviation as an independent predictor of mortality in chronic Chagas' disease. Am J Cardiol 93 (2004) 1136-1140
8. de Andrade A.L., Zicker F., Rassi A., et al. Early electrocardiographic abnormalities in Trypanosoma cruzi-seropositive children. Am J Trop Med Hyg 59 (1998) 530-534
9. Boa Y.F., Traore M.A., Doua F., Kouassi-Traore M.T., Kouassi B.E., and Giordano C. The different present-day clinical picture of human African trypanosomiasis caused by T b gambiense. Analysis of 300 cases from a focus in Daloa, Ivory Coast. Bull Soc Pathol Exot Filiales 81 pt 2 (1988) 427-444 (in French).
10. Le Bras J., Sina G., Triolo N., and Trova P. General symptomatology of human African trypanosomiasis in children. Med Trop (Mars) 37 (1977) 51-61 (in French).
11. Blum J., Schmid C., and Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 97 (2006) 55-64
12. Blum J., and Burri C. Treatment of late stage sleeping sickness caused by T b gambiense: a new approach to the use of an old drug. Swiss Med Wkly 132 (2002) 51-56
13. Jelinek T., Bisoffi Z., Bonazzi L., et al. Cluster of African trypanosomiasis in travelers to Tanzanian national parks. Emerg Infect Dis 8 (2002) 634-635
14. Jones I.G., Lowenthal M.N., and Buyst H. Electrocardiographic changes in African trypanosomiasis caused by Trypanosoma brucei rhodesiense. Trans R Soc Trop Med Hyg 69 (1975) 388-395
15. Boatin B.A., Wyatt G.B., Wurapa F.K., and Bulsara M.K. Use of symptoms and signs for diagnosis of Trypanosoma brucei rhodesiense trypanosomiasis by rural health personnel. Bull World Health Organ 64 (1986) 389-395
16. Pittella J.E. Central nervous system involvement in Chagas' disease. An updating. Rev Inst Med Trop Sao Paulo 35 (1993) 111-116
17. Sartori A.M., Ibrahim K.Y., Nunes Westphalen E.V., et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann Trop Med Parasitol 101 (2007) 31-50
18. Ferreira M.S., Nishioka S.A., Silvestre M.T., Borges A.S., Nunes-Araujo F.R., and Rocha A. Reactivation of Chagas' disease in patients with AIDS: report of three new cases and review of the literature. Clin Infect Dis 25 (1997) 1397-1400
19. Madalosso G., Pellini A.C., Vasconcelos M.J., et al. Chagasic meningoencephalitis: case report of a recently included AIDS-defining illness in Brazil. Rev Inst Med Trop Sao Paulo 46 (2004) 199-202
20. Sartori A.M., Neto J.E., Nunes E.V., et al. Trypanosoma cruzi parasitemia in chronic Chagas disease: comparison between human immunodeficiency virus (HIV)-positive and HIV-negative patients. J Infect Dis 186 (2002) 872-875
21. Rivera J., Hillis L.D., and Levine B.D. Reactivation of cardiac Chagas' disease in acquired immune deficiency syndrome. Am J Cardiol 94 (2004) 1102-1103
22. Simarro P.P., Jannin J., and Cattand P. Eliminating human African trypanosomiasis: where do we stand and what comes next?. PLoS Med 5 (2008) e55
23. WHO. Control and surveillance of African trypanosomiasis. WHO technical report series no. 881 (1998), World Health Organization, Geneva
24. Ginoux P.Y., Frezil J.L., and Alary J.C. Symptoms of human trypanosomiasis at the first diagnostic phase in the People Republic of Congo (author's transl). Med Trop (Mars) 42 (1982) 281-287 (in French).
25. Bertrand E., Serie F., Kone I., et al. General symptomatology of human African trypanosomiasis at the time of screening. Médecine d'Afrique Noire 20 (1973) 303-314 (in French).
26. Kennedy P.G. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 113 (2004) 496-504
27. Blum J.A., Burri C., Hatz C., Kazumba L., Mangoni P., and Zellweger M.J. Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis). Trop Med Int Health 12 (2007) 1422-1432
28. WHO. Control of Chagas disease. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 811 (1991) 1-95
29. WHO. New global effort to eliminate Chagas disease. Wkly Epidemiol Rec 82 (2007) 259-260
30. Schmunis G.A. Epidemiology of Chagas disease in non endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 102 suppl 1 (2007) 75-85
31. Centers for Disease Control and Prevention. Blood donor screening for Chagas disease-United States, 2006-2007. MMWR Morb Mortal Wkly Rep 56 (2007) 141-143
32. Teixeira A.R., Nascimento R.J., and Sturm N.R. Evolution and pathology in chagas disease-a review. Mem Inst Oswaldo Cruz 101 (2006) 463-491
33. Anez N., Carrasco H., Parada H., et al. Myocardial parasite persistence in chronic chagasic patients. Am J Trop Med Hyg 60 (1999) 726-732
34. Mocelin A.O., Issa V.S., Bacal F., Guimaraes G.V., Cunha E., and Bocchi E.A. The influence of aetiology on inflammatory and neurohumoral activation in patients with severe heart failure: a prospective study comparing Chagas' heart disease and idiopathic dilated cardiomyopathy. Eur J Heart Fail 7 (2005) 869-873
35. Dutra W.O., Rocha M.O., and Teixeira M.M. The clinical immunology of human Chagas disease. Trends Parasitol 21 (2005) 581-587
36. Barreto-Filho J.S., Consolim-Colombo F.M., Ferreira L.H., Martins Sobrinho C.R., Guerra-Riccio G.M., and Krieger E.M. Dysregulation of peripheral and central chemoreflex responses in Chagas' heart disease patients without heart failure. Circulation 104 (2001) 1792-1798
37. Villar J.C., Leon H., and Morillo C.A. Cardiovascular autonomic function testing in asymptomatic T cruzi carriers: a sensitive method to identify subclinical Chagas' disease. Int J Cardiol 93 (2004) 189-195
38. Collomb H., and Bartoli D. The heart in human African trypanosomiasis caused by Trypanosoma gambiense. Bull Soc Pathol Exot Filiales 60 (1967) 142-156 (in French).
39. Adams J.H., Haller L., Boa F.Y., Doua F., Dago A., and Konian K. Human African trypanosomiasis (T b gambiense): a study of 16 fatal cases of sleeping sickness with some observations on acute reactive arsenical encephalopathy. Neuropathol Appl Neurobiol 12 (1986) 81-94
40. Morrison W.I., Murray M., Sayer P.D., and Preston J.M. The pathogenesis of experimentally induced Trypanosoma brucei infection in the dog. I. Tissue and organ damage. Am J Pathol 102 (1981) 168-181
41. Bertrand E., Serie F., Rive J., et al. Current aspects of the cardiac symptoms in African human trypanosomiasis due to Trypanosoma gambiense (apropos of 194 cases). Acta Cardiol 29 (1974) 363-381 (in French).
42. Koten J.W., and De Raadt P. Myocarditis in Trypanosoma rhodesiense infections. Trans R Soc Trop Med Hyg 63 (1969) 485-489
43. Viotti R., Vigliano C., Lococo B., et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144 (2006) 724-734
44. Salles G., Xavier S., Sousa A., Hasslocher-Moreno A., and Cardoso C. Prognostic value of QT interval parameters for mortality risk stratification in Chagas' disease: results of a long-term follow-up study. Circulation 108 (2003) 305-312
45. Rassi A., Rassi A., Little W.C., et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 355 (2006) 799-808
46. Carme B., Aune I., Nguyen G., Aznar C., and Beaudet B. Four cases of acute chagasic myocarditis in French Guiana. Am J Trop Med Hyg 64 (2001) 162-163
47. Dias J.C. The indeterminate form of human chronic Chagas' disease. A clinical epidemiological review. Rev Soc Bras Med Trop 22 (1989) 147-156
48. WHO. Control of Chagas disease. WHO technical report series no. 905 (2002), World Health Organization, Geneva
49. Ribeiro A.L., Teixeira M.M., Reis A.M., et al. Brain natriuretic peptide based strategy to detect left ventricular dysfunction in Chagas disease: a comparison with the conventional approach. Int J Cardiol 109 (2006) 34-40
50. Espinosa R., Carrasco H.A., Belandria F., et al. Life expectancy analysis in patients with Chagas' disease: prognosis after one decade (1973-1983). Int J Cardiol 8 (1985) 45-56
51. Ianni B.M., Arteaga E., Frimm C.C., Barretto A.P., and Mady C. Chagas' heart disease: evolutive evaluation of electrocardiographic and echocardiographic parameters in patients with the indeterminate form. Arq Bras Cardiol 77 (2001) 59-62
52. Viotti R., Vigliano C., Armenti H., and Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127 (1994) 151-162
53. Riarte A., Luna C., Sabatiello R., et al. Chagas' disease in patients with kidney transplants: 7 years of experience 1989-1996. Clin Infect Dis 29 (1999) 561-567
54. Rocha M.O., Teixeira M.M., and Ribeiro A.L. An update on the management of Chagas cardiomyopathy. Expert Rev Anti Infect Ther 5 (2007) 727-743
55. Punukollu G., Gowda R.M., Khan I.A., Navarro V.S., and Vasavada B.C. Clinical aspects of the Chagas' heart disease. Int J Cardiol 115 (2007) 279-283
56. Aras R., da Matta J.A., Mota G., Gomes I., and Melo A. Cerebral infarction in autopsies of chagasic patients with heart failure. Arq Bras Cardiol 81 (2003) 414-513
57. Carod-Artal F.J., Ribeiro L.S., and Vargas A.P. Awareness of stroke risk in chagasic stroke patients. J Neurol Sci 263 (2007) 35-39
58. Carod-Artal F.J., Vargas A.P., Horan T.A., and Nunes L.G. Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease. Stroke 36 (2005) 965-970
59. Carod-Artal F.J. Chagas cardiomyopathy and ischemic stroke. Expert Rev Cardiovasc Ther 4 (2006) 119-130
60. Bestetti R.B., and Muccillo G. Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol 60 (1997) 187-193
61. Maguire J.H. Chagas' disease-can we stop the deaths?. N Engl J Med 355 (2006) 760-761
62. Viotti R., Vigliano C., Lococo B., et al. Clinical predictors of chronic chagasic myocarditis progression. Rev Esp Cardiol 58 (2005) 1037-1044 (in Spanish).
63. Salles G.F., Cardoso C.R., Xavier S.S., Sousa A.S., and Hasslocher-Moreno A. Electrocardiographic ventricular repolarization parameters in chronic Chagas' disease as predictors of asymptomatic left ventricular systolic dysfunction. Pacing Clin Electrophysiol 26 (2003) 1326-1335
64. Corbucci H.A., Haber D.M., Bestetti R.B., Cordeiro J.A., and Fioroni M.L. QT interval dispersion in patients with chronic heart failure secondary to Chagas' cardiomyopathy: correlation with clinical variables of prognostic significance. Cardiovasc Pathol 15 (2006) 18-23
65. Rochitte C.E., Oliveira P.F., Andrade J.M., et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J Am Coll Cardiol 46 (2005) 1553-1558
66. Acquatella H. Echocardiography in Chagas heart disease. Circulation 115 (2007) 1124-1131
67. Viotti R.J., Vigliano C., Laucella S., et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart 90 (2004) 655-660
68. Mora M.C., Sanchez N.O., Marco D., et al. Early diagnosis of congenital Trypanosoma cruzi infection using PCR, hemoculture, and capillary concentration, as compared with delayed serology. J Parasitol 91 (2005) 1468-1473
69. Arias R., Bastos C., Mota G., et al. Troponin in chagas disease. Braz J Infect Dis 7 (2003) 358-359
70. Basquiera A.L., Capra R., Omelianiuk M., Amuchastegui M., Madoery R.J., and Salomone O.A. Serum troponin T in patients with chronic Chagas disease. Rev Esp Cardiol 56 (2003) 742-744 (in Spanish).
71. Ribeiro A.L., dos Reis A.M., Barros M.V., et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. Lancet 360 (2002) 461-462
72. Heringer-Walther S., Moreira M.C., Wessel N., et al. Brain natriuretic peptide predicts survival in Chagas' disease more effectively than atrial natriuretic peptide. Heart 91 (2005) 385-387
73. Talvani A., Rocha M.O., Cogan J., et al. Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. Mem Inst Oswaldo Cruz 99 (2004) 645-649
74. Talvani A., Rocha M.O., Cogan J., et al. Brain natriuretic peptide measurement in Chagas heart disease: marker of ventricular dysfunction and arrhythmia. Int J Cardiol 100 (2005) 503-504
75. Barbosa M.M., Nunes M.C.P., Ribeiro A.L., Barral M.M., and Rocha M.O. N-terminal proBNP levels in patients with Chagas disease: a marker of systolic and diastolic dysfunction of the left ventricle. Eur J Echocardiogr 8 (2007) 204-212
76. de Andrade A.L., Zicker F., de Oliveira R.M., et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348 (1996) 1407-1413
77. Cancado J.R. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 44 (2002) 29-37
78. Sosa E.S., Segura E.L., Ruiz A.M., Velazquez E., Porcel B.M., and Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 59 (1998) 526-529
79. Bern C., Montgomery S.P., Herwaldt B.L., et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 298 (2007) 2171-2181
80. Viotti R., and Vigliano C. Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine. Expert Rev Anti Infect Ther 5 (2007) 717-726
81. Khoury A.M., Davila D.F., Bellabarba G., et al. Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure. Int J Cardiol 57 (1996) 21-29
82. Gascon J., Albajar P., Canas E., et al. Diagnosis, management and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic. Rev Esp Cardiol 60 (2007) 285-293 (in Spanish).
83. Epstein A.E., Dimarco J.P., Ellenbogen K.A., et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 51 (2008) e1-e62
84. Leite L.R., Fenelon G., Simoes A., Silva G.G., Friedman P.A., and de Paola A.A. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. J Cardiovasc Electrophysiol 14 (2003) 567-573
85. Martinelli F.M., De Siqueira S.F., Moreira H., et al. Probability of occurrence of life-threatening ventricular arrhythmias in Chagas' disease versus non-Chagas' disease. Pacing Clin Electrophysiol 23 (2000) 1944-1946
86. Muratore C., Rabinovich R., Iglesias R., Gonzalez M., Daru V., and Liprandi A.S. Implantable cardioverter defibrillators in patients with Chagas' disease: are they different from patients with coronary disease?. Pacing Clin Electrophysiol 20 (1997) 194-197
87. Bocchi E.A., and Fiorelli A. The Brazilian experience with heart transplantation: a multicenter report. J Heart Lung Transplant 20 (2001) 637-645
88. Fiorelli A.I., Stolf N.A., Honorato R., et al. Later evolution after cardiac transplantation in Chagas' disease. Transplant Proc 37 (2005) 2793-2798
89. Diez M., Favaloro L., Bertolotti A., et al. Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation. Am J Transplant 7 (2007) 1633-1640
90. Bacal F., Silva C.P., Bocchi E.A., et al. Mychophenolate mofetil increased Chagas disease reactivation in heart transplanted patients: comparison between two different protocols. Am J Transplant 5 (2005) 2017-2021
91. Bertrand E., Serie F., Rive J., et al. Cardiovascular symptomatology in human African trypanosomiasis caused by Trypanosoma gambiense. Médecine d'Afrique Noire 20 (1973) 327-339 (in French).
92. Tsala M.P., Blackett K., Mbonifor C.L., Leke R., and Etoundi J. Functional and immunologic involvement in human African trypanosomiasis caused by Trypanosoma gambiense. Bull Soc Pathol Exot Filiales 81 (1988) 490-501 (in French).
93. Fouchet M., and Gateff C. Development of cardiovascular involvement in African trypanosomiasis due to Trypanosoma gambiense. Med Trop (Mars) 28 (1968) 583-590 (in French).
94. Damian M.S., Dorndorf W., Burkardt H., Singer I., Leinweber B., and Schachenmayr W. Polyneuritis and myositis in Trypanosoma gambiense infection. Dtsch Med Wochenschr 119 (1994) 1690-1693 (in German).
95. Chappuis F., Loutan L., Simarro P., Lejon V., and Buscher P. Options for field diagnosis of human African trypanosomiasis. Clin Microbiol Rev 18 (2005) 133-146
96. Becker S., Franco J.R., Simarro P.P., Stich A., Abel P.M., and Steverding D. Real-time PCR for detection of Trypanosoma brucei in human blood samples. Diagn Microbiol Infect Dis 50 (2004) 193-199
97. Costello-Boerrigter L.C., Boerrigter G., Redfield M.M., et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 47 (2006) 345-353
98. Blum J.A., Schmid C., Hatz C., et al. Sleeping glands? The role of endocrine disorders in sleeping sickness (T b gambiense human African trypanosomiasis). Acta Trop 104 (2007) 16-24
99. Blum J., Nkunku S., and Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 6 (2001) 390-400
100. Burri C., Nkunku S., Merolle A., Smith T., Blum J., and Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355 (2000) 1419-1425
101. Poltera A.A., Hochmann A., and Lambert P.H. Trypanosoma brucei brucei: the response to melarsoprol in mice with cerebral trypanosomiasis. An immunopathological study. Clin Exp Immunol 46 (1981) 363-374
102. Poltera A.A., Cox J.N., and Owor R. Pancarditis affecting the conducting system and all valves in human African trypanosomiasis. Br Heart J 38 (1976) 827-837
103. Poltera A.A., Hochmann A., and Lambert P.H. A model for cardiopathy induced by Trypanosoma brucei brucei in mice. A histologic and immunopathologic study. Am J Pathol 99 (1980) 325-351
104. Pepin J., Tetreault L., and Gervais C. The use of oral corticosteroids in the treatment of human African trypanosomiasis: a retrospective survey in Nioki, Zaire. Ann Soc Belg Med Trop 65 (1985) 17-29 (in French).
105. Blackett K., and Ngu J.L. Immunological studies in congestive cardiomyopathy in Cameroon. Br Heart J 38 (1976) 605-611
106. Blum J., Beck B.R., Brun R., and Hatz C. Clinical and serologic responses to human "apathogenic" trypanosomes. Trans R Soc Trop Med Hyg 99 (2005) 795-797
107. De Raadt P., and Koten J.W. Myocarditis in Rhodesiense trypanosomiasis. East Afr Med J 45 (1968) 128-132
108. Grau Junyent J.M., Rozman M., Corachan M., Estruch R., and Urbano-Marquez A. An unusual course of west African trypanosomiasis in a Caucasian man. Trans R Soc Trop Med Hyg 81 (1987) 931-932
109. Manson-Bahr P., and Chartres A.D. Myocarditits in African trypanosomiasis. Trans R Soc Trop Med Hyg 57 (1963) 119-121